Psychiatric disorders are clinically heterogeneous and debilitating chronic diseases resulting from a complex interplay between gene variants and environmental factors. Epigenetic processes, such as DNA methylation and histone posttranslational modifications, instruct the cell/tissue to correctly interpret external signals and adjust its functions accordingly. Given that epigenetic modifications are sensitive to environment, stable, and reversible, epigenetic studies in psychiatry could represent a promising approach to better understanding and treating disease. In the present review, we aim to discuss the clinical opportunities and challenges arising from the epigenetic research in psychiatry. Using selected examples, we first recapitulate key findings supporting the role of adverse life events, alone or in combination with genetic risk, in epigenetic programming of neuropsychiatric systems. Epigenetic studies further report encouraging findings about the use of methylation changes as diagnostic markers of disease phenotype and predictive tools of progression and response to treatment. Then we discuss the potential of using targeted epigenetic pharmacotherapy, combined with psychosocial interventions, for future personalized medicine for patients. Finally, we review the methodological limitations that could hinder interpretation of epigenetic data in psychiatry. They mainly arise from heterogeneity at the individual and tissue level and require future strategies in order to reinforce the biological relevance of epigenetic data and its translational use in psychiatry. Overall, we suggest that epigenetics could provide new insights into a more comprehensive interpretation of mental illness and might eventually improve the nosology, treatment, and prevention of psychiatric disorders.
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depressive disorder (MDD) disorders, due to coinheritance of risk genes, with an estimation of genetic heritability of SCZ and BD in the range 70-80% [3] [4] [5] and of depression between 48% and 75%. 6 However, the majority of these data is not sufficient to discriminate the relative roles of genes and shared early environment and might result in an overestimation of genetic heritability. Genomewide association studies (GWAS) conducted in large case-control cohorts have enabled the identification of specific single nucleotide polymorphisms associated with psychiatric phenotypes at the population level, most of them being shared among diseases. 7, 8 These studies support a polygenic model with many common variants, each conferring modest effects. They further indicate that a limited part of the disease can be explained by genetic variants compared to twin-based heritability estimates. 7, 8 The significant gap in heritability for some severe diseases, such as SCZ and BD, shed light on a 'hidden' heritability that may in part be driven by nongenetic processes, such as gene-environment interactions. Extensive epidemiological studies have identified a large number of environmental factors during the perinatal, childhood, and adulthood stages of an individual's life. 9 Additional environmental parameters, such as the nature, severity, developmental timing, and temporal pattern (acute vs chronic), of both adverse and favorable exposures are likely to account for the inter-individual heterogeneity of life-course trajectories. Notably, the individual sensitivity to environmental factors could be, at least partly, influenced by genetic factors, whereby genotypes can exacerbate or mitigate an individual's susceptibility to environmental influence. 10 Altogether, the model of synergy between genetic and environmental risk factors (Fig. 1a) positions seemingly static genetics into a dynamic context where predisposing variants might not account for the same proportion of the susceptibility to a psychiatric disorder under all circumstances. Understanding the relative contributions and potential interactions of genetic and environmental factors on the phenotypic manifestation seems therefore crucial to better understanding and treating psychiatric disorders.
EPIGENETICS
Epigenetic research is at the epicenter of modern medicine due to its opportunity to investigate the interaction between genetic and environmental risk factors. The term 'epigenetics' was first coined in the early 1940s by Conrad Waddington to explain the involvement of gene-environment interaction during development. Epigenetics, which literally means 'on top of the genes,' refers to mitotically and meiotically heritable changes in gene expression that do not entail variation in the DNA sequence. Epigenetic processes are therefore primarily of non-genetic origin, with environmental influence accounting for most of the variance, 11 and transmitted through cell division.
Epigenetic mechanisms instruct the cell to correctly interpret internal (genes) and external (environment) signals and adjust accordingly. They rely on the deposition of biochemical modifications onto the genome, either on the DNA itself, such as DNA methylation, or on the regulatory proteins bond to the DNA, such as histone posttranslational modifications (PTM), all of which represent the epigenome (Fig. 1b) . Once fixed onto the genome, epigenetic modifications are chemically stable and faithfully maintained during cell division thereby perpetuating the phenotypic adjustment to the daughter cell. They act in concert to shape the chromatin toward a specific level of compaction and allow, or inversely impede, the accessibility of genes to regulatory transcriptional factors. For example, the most studied epigenetic mark, DNA methylation, is traditionally considered as a mark of transcriptional repression when associated to the promoter region of genes. 12 A more flexible definition of epigenetic processes also encompasses the regulatory action of long and small non-coding RNA (such as lncRNA and miRNA), although these processes are not believed to induce long-lasting heritable epigenetic states (Fig. 1b) .
The importance of epigenetics in mental illness first arose from the discovery of mutations in genes involved in the epigenetic machinery (readers, writers, or erasers of epigenetic modifications) in cases of neurodevelopmental and intellectual disability disorders, such as the Rett's and fragile X syndromes. 13 Given that epigenetic modifications are sensitive to environment, stable, and reversible, epigenetic studies in psychiatry might represent a promising approach to better understanding and treating disease. In the present review, we aim to discuss the clinical opportunities and challenges arising from the epigenetic research in psychiatry. 
POTENTIAL USE OF EPIGENETICS FOR MECHANISTIC INSIGHT AND NOVEL BIOMARKERS
The study of epigenetic processes offers a promising perspective for an improved understanding of the complexity of psychiatric disorders and the discovery of novel biomarkers of disease phenotype and progression. The attractiveness of epigenetic research in psychiatry is reflected by the flourishing number of articles and reviews; 14, 15 therefore, in the next section, we aim to summarize some key findings with selected examples brought by epigenetic research toward a better appreciation of mental illness. These results are summarized in Figure 1c ,d.
Epigenetic programming of neuropsychiatric systems by adverse life experience
A variety of rodent models are currently being used to decipher the molecular basis of stress response in general, and epigenetics of early life adversity in particular. 16 The most consistent finding evidenced in rodents that has been subsequently translated to humans is the epigenetic programming of genes of the hypothalamic-pituitary-adrenal (HPA) axis by early-life maltreatment. A seminal study from Weaver et al. has revealed that the epigenetic status (measured by histone PTM) of the glucocorticoid receptor (GR) gene Nr3c1 in the hippocampus of the rat was associated with the quality of parental care of the pups, the levels of GR, and vulnerability to stress. 17 This observation was further confirmed in humans by the detection of DNA methylation changes in the NR3C1 gene in the hippocampus of suicide victims with a history of childhood abuse, compared to suicide victims or controls with no reported childhood abuse. 18, 19 Notably, the altered GR levels induced by DNA methylation impair negative feedback of the HPA axis so that stress responses become inadequately regulated. 20, 21 Since these pioneer studies, numerous reports have extended the investigation of the methylation status of the NR3C1 gene to several other rodent and human conditions. The latter include exposure to childhood emotional, physical, or sexual abuse, neglect and/or parental death, and/or in the context of psychopathology, such as borderline personality disorder (BPD, also known as emotional unstable personality disorder), bulimia nervosa, post-traumatic stress disorder (PTSD), and depression. The majority of the studies have consistently detected DNA methylation changes in the NR3C1 gene either in peripheral blood and/or brain limbic and cortical structures in exposed or diseased individuals. 22 However, despite compelling evidence of the association between early life adversity and increased NR3C1 methylation, studies conducted in the context of psychopathology have yielded more varied results regarding the direction of changes 22 and this lack of consensus thus warrants further investigation. Interestingly, the amplitude of DNA methylation changes at the GR gene in adults suffering from psychiatric disorders could be correlated with the severity and repetition of the maltreatments in childhood, as for cases of childhood sexual abuse. 23 Finally, recent studies have disentangled the effect of adversity on sustained hyperactivity of the HPA axis and related impaired behavioral response to stress by showing epigenetic alterations in other key players of the HPA axis. These involve the intracellular GR regulator FKBP5 gene, as well as the hypothalamic arginine vasopressin (AVP), corticotropin-releasing hormone (CRH), and pituitary proopiomelanocortin (POMC) genes. 24 Besides the neuroendocrine HPA axis, the epigenetic status of other neuropsychiatric systems has been examined in relation to stressful life experience and/or psychiatric disorders. This is the case for the brain-derived neurotrophic factor (BDNF) gene, encoding one of the most prevalent growth factors in the brain, which plays important roles in development, plasticity, and survival of a large number of neuronal subtypes. 25 Studies of stress-induced depression and PTSD models in the rat have shown that childhood or adult trauma induces long-lasting repressive epigenetic marks of the Bdnf gene in the brain, these modifications being associated with lower levels of Bdnf expression and depressive-like behavior. 26, 27 Experience-induced epigenetic regulation of the BDNF gene could be further translated to humans, with the BDNF gene displaying higher DNA methylation levels in peripheral blood cells from adults who have been previously exposed to low childhood maternal care compared with those exposed to high childhood maternal care. 28 Likewise, repressive hypermethylation of the BDNF gene was detected in the blood of depressed patients compared to controls, 29 the levels of changes being further associated with previous history of suicidal attempts, ideation, and poor response to antidepressant treatment. 30 Finally, numerous studies have identified DNA methylation differences in the epigenetic status of the BDNF or its cognate receptor TRKB genes in peripheral blood of patients from other psychiatric disorders with depressive features and in postmortem brains from suicide-completers, including those with MDD, BD, SCZ, and BPD. 31 Likewise, the gene encoding the serotonin transporter, defined by different names, such as 5-HTT, SLC6A4 and SERT, has been shown to display epigenetic changes in relation to several environmental stressors occurring throughout life, neuroimaging variables (volume and network of limbic tissues), as well as psychopathological disorders, such as MDD, BD, PTSD, SCZ, attention deficit hyperactivity disorder (ADHD), and addiction (reviewed in detail by Palma-Gudiel and Fañanás
32
). These findings are interesting in light of the genetic association of polymorphism within the 5-HTT promoter with a number of psychiatric conditions (described in the next section) and the pharmacological development of selective serotonin reuptake inhibitor targeting 5-HTT as a first-line treatment for depression and anxiety disorders.
The recent advancement in epigenome-wide analyses has advanced the field beyond a genecandidate approach towards a more comprehensive mapping of the neuroepigenome. In this regard, life exposure-and phenotype-specific epigenome signatures are constantly being generated, as in the case of childhood maltreatment, 33 MDD, 34 BD, 35 SCZ, 36 autism spectrum disorder, 37,38 eating disorders 39 and shared features, such as suicidality 31 or psychosis. 40, 41 These epigenomic studies have uncovered dysregulation of multiple biological pathways, including the previously identified HPA, monoaminergic, and neurotrophin systems. In addition to these classical pathways, epigenetic alteration of the glutamatergic, GABAergic, Reelin, and polyamine systems, among others, have been detected in brains from affected individuals. Finally, recent studies have identified epigenetic disturbance of glial genes from oligodendrocytes 42, 43 and astrocytes, 44, 45 highlighting the relevance of neuroglial communication, myelination, and neuroinflammatory processes in the pathogenesis of psychiatric disorders.
Cross talk between the genome and the epigenome in the vulnerability to stress and psychiatric disorders GWAS studies have provided an ever-growing catalog of genetic variations associated with psychiatric phenotypes and have further shed light of shared and unique components of mental illness. 7, 8 They reveal that the genetic architecture of psychiatric disorders is highly complex, polygenic, and related to common variations rather than abnormal mutations. A key challenge now is to place the identified variants in the context of pathological mechanisms. In this context, Rutter et al. have recommended elucidating more specifically genes that predispose to disease through their effect on sensitivity to environmental risk. 46 In line with this, integrated approaches combining the multiple layers of the interplay between genetic and epigenetic factors in gene regulation have shown that, overall, a substantial fraction of the epigenome is controlled by the DNA sequence. [47] [48] [49] This genetic-epigenetic paradigm thus appears instrumental to understanding how genes and life adversity shape individuals into vulnerability or resilience states.
One of the strongest evidences of interaction between risk variant and DNA methylation involves the aforementioned serotonin transporter 5-HTT/ SLC6A4 gene. Variation in the DNA sequence of the promoter of the gene, 5-HTTLPR, distinguishes short (S) from long (L) alleles with, respectively, low or high SLC6A4 expression and serotonin uptake. Initial work from Caspi et al. has reported that carriers of the S alleles exhibited higher suicidality after exposure to a stressful life event compared to noncarriers (LL homozygotes), without altering risk in absence of stress events. 50 Yet, the moderating impact of 5-HTTLPR on the interaction between stressful life event and depression remains debated, as meta-analyses could either contradict 51 or support 52 this effect. By simultaneously assessing SLC6A4 methylation in cohorts genotyped for 5-HTTLPR, numerous studies have reported a moderator effect of 5-HTTLPR polymorphism on SLC6A4 gene DNA methylation in association with stressful life events (such as childhood abuse, neighborhood crime, or socioeconomic status) and with psychopathological risk, such as depressive symptoms, antisocial personality disorder, or antidepressant response. 32 Notably, while in some cases, only S allele carriers were found to be epigenetically susceptible to stressful life events, in others instances, only the LL homozygotes showed correlation between DNA methylation changes and exposure to stress, thus suggesting context-specific effects. 32 Similarly, a genetic-stress-epigenetic interaction has been shown for the regulation of the FKBP5 gene, a central regulator of stress responsivity as a component of the GR complex. Expression of this co-chaperone is induced by GR activation and it participates in the intracellular negative feedback loop of GR activity. A large body of evidence supports an association between risk variant-mediated high FKBP5 expression and a variety of stressful life events and psychiatric disorders and traits, including PTSD, depression, aggression, suicide, and psychosis. 53 Interestingly, co-localization of genetic risk and epigenetic changes can occur in the context of exposure to early trauma (e.g. childhood neglect/ abuse) where exacerbated activation of the FKBP5 risk variant results in active demethylation of a distal regulatory locus within the gene. The subsequent hypomethylation of this region leads to even more pronounced FKBP5 expression, further sensitizing GR to future exposure. 54 This disinhibition of the GR sensitivity and subsequently impaired HPA axis result in an aggravated and prolonged stress response, alteration of stress-related circuits, synaptic plasticity, and emotion-processing brain structures, that will ultimately affect stress-coping and vulnerability to psychiatric disorders. 53 At the genome-wide level, analyses of genetic and DNA methylation variations in fetal post-mortem brains from aborted pregnancies have identified regions where DNA methylation was under local genetic control. 55 These genetically dependent DNA methylation domains showed strong developmental stability as they remained in the adult normal brain and, importantly, were enriched for risk loci for SCZ. Occurrences of genetic and epigenetic traits in fetal brain further support a neurodevelopmental determinant to schizophrenia. 55 Furthermore, a comprehensive study integrating genomic and epigenomic analyses in a large case-control cohort of SCZ patients has found that DNA methylation variation was associated with polygenic burden for SCZ disease and further overlapped with schizophrenia GWAS loci. 56 Additionally, the risk variants co-localized with genetically controlled DNA methylation regions. 56 The discovery of multiple DNA methylation loci under genetic influence is in line with candidate-gene approaches showing genetically dependent epigenetic status at other risk genes, including the GABA receptor subunit (GABRB2), 57 catechol-O-methyltransferase (COMT [58] [59] [60] and cannabinoid receptor (CNR1 61 risk genes, involved in neurotransmission alone or in combination with established environmental risk factors, such as cannabis smoking.
Thus, even though epigenetic research in psychiatry is still in its infancy, the studies show promise for a better understanding of how transient or chronic life events, alone or in combination with susceptible genes, can lead to alterations of neuropsychiatric systems, visible at the molecular level with epigenetic modifications. The relevance of epigenetic changes lies in their potential to alter the adaptability of the organism to upcoming life challenges by changing the likelihood of an individual to manifest vulnerability or resilience to future stressors (Fig. 1c,d ).
Potential use of epigenetic modifications as biomarkers
Despite progress in identifying the molecular mechanisms underlying psychiatric disorder, valid biomarkers are still lacking for both disease phenotyping and treatment response. Importantly, some epigenetic changes can be stable throughout time and be detected in patients' blood and/or post-mortem brain decades after exposure to a trauma. This stability has been evidenced for instance in individuals who were prenatally exposed to war-related negative environment and exhibited persistent DNA methylation changes in absence of continued adverse exposure, as they could be detected decades later compared to the control groups. 62, 63 The sensitivity and stability of epigenetic marks make them promising candidates for robust biomarkers. Undoubtedly, correlation of some DNA methylation changes between post-mortem brain and peripheral blood cells 64 advocates the use of DNA methylation as additional biological information improving diagnosis and prognosis. Emerging studies have reported encouraging results concerning the use of methylation changes as diagnostic tools for behavioral and clinical precision phenotyping of patients. [65] [66] [67] A longitudinal study has shown association between SP6 gene DNA methylation, amygdala/ hippocampal volume ratio, and psychopathology, 68 supporting the role of DNA methylation as a longitudinal epigenetic predictor. Moreover, blood methylation levels of 5-HTT and/or BDNF genes have been suggested as promising biomarkers for prediction of pharmacological or psychotherapeutic treatment response in patients suffering from MDD, 69 BD, BPD, 70 PTSD, 71 SCZ 72 and ADHD. 73 In addition to these genes, recent studies have reported a four-locus model involving the CYP3A4 gene that significantly alters risperidone treatment response of SCZ patients. 74 Finally, the generation of a DNA methylation biosignature in blood or saliva has been shown to improve a suicide-prediction model. 75 Some novel approaches based on multiplex DNA methylation profile, 75 methylation specificquantitative analysis 67 and droplet/digital PCR assay 76 promise new avenues for early, specific, and quantitative detection of phenotype-associated DNA methylation signature in combination with other biomarkers.
EPIGENETIC PERSPECTIVE TO AN INTEGRATED AND PERSONALIZED TREATMENT OF PATIENTS WITH PSYCHIATRIC DISORDERS
In a graphical adaptation of Waddington's epigenetic landscape to psychiatric outcome, the unique load of genetic and environmental influences would direct the individual, depicted as a ball, along specific valleys of resilience or vulnerability to adversity and at intermediate states of bifurcation (Fig. 2a) . 77 These intermediate transitional points appear as discrete sub-critical stages that retain high susceptibility to changes and mediate conversion from physiological to psychopathological states and vice versa. This further highlights the relevance of a shift toward a 'plasticity' rather than susceptibility paradigm, where 'vulnerability' genes may in reality act as 'plasticity' genes rendering some individuals more responsive than others to both positive and negative life experiences. 78 In this conceptual framework, it is tempting to speculate about the potential of using epigenetics as a mediator of plasticity in therapeutic approaches (Fig. 2b) . Indeed, even with the development of potent psychotropic agents, the efficacy of current pharmacological agents shows limitations, and treatment of patients in psychiatry remains challenging. Because epigenetic modifications are reversible by nature, they might represent novel targets for therapeutic improvement. In the next section, we describe emerging evidence that supports the potential of using pharmacological and psychotherapeutic approaches targeting epigenetic programming for the treatment of psychiatric disorders.
Epigenetic pharmacotherapy
The plastic nature of epigenetic marks offers the possibility to modulate and possibly correct epigenetic alterations through classical pharmacology. 79 Epigenetic machinery comprises a variety of DNA/histone modifiers and epigenetic medicine commonly falls into two main categories: DNA methyltransferase (DNMT) inhibitors acting on DNA methylation (such as 5-aza (2'deoxy)cytidine or decitabine); and histone deacetylase (HDAC) inhibitors, such as valproic acid (VPA) or trichostatin A, targeting histone PTM. Even though the efficacy of DNMT inhibitors has been recognized in the context of cancer, their therapeutic potential in treatment of psychiatric disorders is still at the preclinical stage. Indeed, their action depends on DNA replication during cell division and can elicit neurotoxic effects, 80 therefore limiting their potential use for nonmalignant brain diseases. On the contrary, the HDAC inhibitor VPA has a long history of use in the treatment of bipolar disorders and epilepsy as an anticonvulsant and mood-stabilizer. 81 In animal models, commonly used HDAC inhibitors could reportedly enhance synaptic plasticity, alleviate cognitive and neurological defects, and, importantly, mimic the effect of antidepressant or fear memory extinction in models of depression and PTSD. 82, 83 Furthermore, in a rodent model of schizophrenia, VPA has been found to mediate a beneficial impact, alone or in combination with antipsychotic drug, through action on DNA methylation. 84 However, the use of global epigenetic modifiers, such as DNMT or HDAC inhibitors, may elicit limitations for clinical purposes, such as global epigenetic manipulations exerting broad effect on the epigenome (regulating multiple genes) with possible adverse side-effects (e.g. teratogenicity 81 ). One approach to overcome the global effect of DNMT and HDAC inhibitors would be to utilize targeted epigenetic strategies, which aim at correcting putative pathogenic marks exclusively and leaving the homeostatic 'beneficial' marks unchanged. Among the epigenome editing tools available in animal experimentation, the recently developed CRISPR-dCas9 system appears to be a promising strategy for targeted epigenetic therapy. The CRISPRdCas9 system relies on the coupling of a guide single RNA targeting a specific locus of the genome and a deactivated endonuclease dCas9 fused to the catalytic domain of an epigenetic enzyme. Recent seminal studies have suggested the potential of using a CRISPR-dCas9 approach to inducing long-lasting changes in DNA methylation [85] [86] [87] or histone PTM 88, 89 in-vitro and in-vivo in rodents. Of special interest, in cultured mouse neurons, the CRISPRdCas9 epimodifier complex has been shown to demethylate the Bdnf gene specifically, activating its expression in a long-lasting manner. 90 The attractiveness of targeted epigenetic therapy would therefore rely on its long-lasting, albeit reversible, action thus possibly limiting chronic or repeated administration in patients. One additional challenge to overcoming the residual side-effects of targeted epigenetic therapy is the tissue-specificity of the therapeutic effect. In that regard, novel approaches using natural or synthetic carrier nanoparticles 91 would provide useful tools for specific delivery of epimodifier to the central nervous system. Thus, although very preliminary, these promising data allowing targeted epigenome editing and tissue-specific nanomedicine have set a novel stage for future personalized epigenetic medicine.
Personalized biopsychosocial approach: A model of enriched environment favoring epigenetic reprogramming
Despite proof of effectiveness of psychotherapy alone or in combination with medication, the benefit of psychological or psychosocial interventions in treatment of severe psychiatric disorders appears sometimes underestimated and underused. 92 Undoubtedly, the ideal intervention would be to either prevent early trauma and/or to mitigate its long-term impact, as evidenced in rodents by the seminal work of Meaney. 93 Knowing that critical developmental windows are decisive for potentially long-lasting deleterious epigenetic effect, child psychiatry appears of high relevance to correct epigenetic insults in situ. Alternatively, several animal studies have shown that psychoenvironmental intervention at adulthood allowed rescuing early stressinduced epigenetic programming. Treatment of young adult mice with a supportive enriched environment (EE) could improve depression more effectively than antidepressant, 94 alleviate extreme genetic predispositions to anxiety-related behavior in mice 95 and ameliorate cognitive impairment induced by early life stress. [96] [97] [98] [99] In these studies, the beneficial effects of EE treatment were mediated by such transgenerational epigenetic inheritance of favorable experience being suggested in humans as well. 101 Finally, accumulating evidence from human studies supports a positive regulation of psychotherapy on the epigenetic state of patients suffering from anxiety disorders, 102,103 PTSD 71 or BPD. 70 Altogether, these findings strongly suggest that implementing an enriched environment with psychosocial therapy would aid reprogramming of early stressinduced epigenetic scars in patients. In that regard, importance should be given to the multidimensional character of such an approach, engaging multiple partners from psychiatrists to psychologists, nurses, social workers, relatives, and any other relevant facilitators. Combined pharmacological and EE interventions would consolidate the molecular substrate (e.g., neurotransmitters and neurotrophic factors) and reinforce the epigenetic remodeling necessary for successful reprogramming. Altogether, discoveries from the epigenetic research further encourage the application of a biopsychosocial approach in the care of patients suffering from psychiatric disorders.
CURRENT CHALLENGES IN EPIGENETIC STUDIES AND FUTURE PERSPECTIVE
Even though epigenetic data in psychiatry are continuously growing, their interpretation remain challenging due to methodological and biological limitations. In the next section and in Figure 3a , we summarize some of these challenges, which are common to other complex diseases in general and to central nervous system pathologies in particular.
Cohort and tissue heterogeneity
Since epigenetic processes are sensitive to external influence and represent the molecular substrate of cellular and tissue specificity, possible confounders might bias proper interpretation of epigenetic data. At the individual level, heterogeneity of cohort characteristics, such as age, 104 sex, 105 ethnicity 106 or smoking status 107 might significantly impact the epigenetic results, as evidenced by the sex-specific impact of early life adversity on the methylome. [108] [109] [110] Additionally, a variety of other parameters associated with symptom and treatment heterogeneity likely affects the epigenome and therefore could account for some of the signals detected in epigenetic studies. Thus, the use of large and homogenous samples, cohorts, and experimental models further warrants successful interpretation of the data. An additional limitation for epigenetic research in psychiatry relies on tissue heterogeneity, with a poor accessibility of the target tissue. 111 Epigenetic studies focusing on post-mortem brain tissue are restricted to the most stable and reliable epigenetic mark in such tissue (i.e. DNA methylation), thereby limiting comprehensive understanding of genome activity in situ. Importantly, the brain displays varying epigenetic profiles across brain areas, 112 cell type 113 and even neuronal subtypes. 114, 115 Thus, DNA methylation changes detected in brain biopsies from psychiatric patients could reflect variation in cell composition between patients and controls rather than pathophysiological changes. This is supported by variation in DNA methylation changes between neurons and glial cells in depressed patients 116 and further underscores the need to take cell heterogeneity into account in epigenetic analyses. To address this issue, one approach relies on analytical strategies of correction of the data for cellular composition using reference-based 117, 118 or reference-free algorithms. [119] [120] [121] Alternatively, the ideal way to reduce cellular heterogeneity consists of isolating specific cell types, using, for example, antibodybased sorting of neuronal or glial nuclei prior to DNA methylation analysis. 116 
Technical challenges
Given the difficulty to address and interpret histone PTM in clinical samples, the choice of DNA methylation, with CpG being either methylated or unmethylated, to characterize genome activity appears convenient in clinical studies. Among the technologies available to study epigenetic modification, the use of cost-effective commercial DNA methylation platforms, such as Infinium HumanMethylation BeadChips, offers the best compromise to reliably detect changes in clinical samples. However, even though these so-called genome-wide arrays cover~99% of Refseq genes as well as intergenic regulatory features, they only annotate a small fraction of total CpG. 122 Moreover, most DNA methylation analyses are based on the bisulfite (BS) treatment of the DNA prior to hybridization on array. BS treatment converts unmethylated cytosines into thymine leaving methylated cytosines unchanged, and thus allows estimating methylation at CpG site using signals from each base. Yet, by changing most cytosines located at non-CpG sites into thymines, BS conversion of DNA therefore reduces the complexity of a substantial portion of the genome to three bases, impeding proper investigation of highly polymorphic regions of the genome. Furthermore, the brain is atypical with regards to its unique epigenetic features with a particular enrichment of non-classical DNA modifications, namely hydroxymethylation and non-CpG methylation in neurons. Notably, DNA hydroxymethylation exerts the opposite effect on transcription regulation compared to DNA methylation 123, 124 while non-CpG methylation seems to correlate better than classical CpG methylation with transcriptional repression when located at promoter of genes. 114, 115 It is noteworthy that conventional BSbased arrays do not cover sufficient non-CpG nor allow distinguishing 'true' methylation from hydroxymethylation, thereby leading to mixed signals of both modifications. In that context, emerging technologies, such as oxidative BS 125 or Tet-assisted BS 126 along with the generalization of sequencing methodologies will likely provide new tools for investigation of these regulatory brain-specific marks.
Finally, despite their extensive use, DNA methylation arrays bear analytical challenges at each stage of © 2018 The Authors Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology the experimental pipeline. For example, different signal processing and normalization approaches, as well as adjustment for confounders can be applied. 127 Moreover, the use of gene ontology analyses that were primarily developed for gene expression data poses challenges for interpretation of epigenetic data, 128 as intergenic changes are not annotated to a specific gene. Altogether, these considerations highlight the need for standardized guidelines to analyze DNA methylation changes for replication purposes.
Biological relevance
The functional relevance of DNA methylation is still limited due to our (still) partial knowledge on the consequence of certain modifications in gene expression. This is the case, for instance, with regards to the location (promoter, intragenic, intergenic), the effect size or the nature (single vs multiple adjacent CpG) of the change, which, combined with the type of modification, prevent proper understanding of the results. A multilayered approach combining epigenetics and transcriptomics in relevant tissue thus appears essential for comprehensive interpretation of the data. Alternatively, the use of publicly available databases from ENCODE, Roadmap 129 and the recently published brain genome-epigenome-transcriptome data base 130 could aid in exploring the putative consequences of DNA methylation data.
The biological relevance of epigenetics in human complex diseases, such as psychiatric disorders, is further complicated by the difficulty to infer causality between epigenetic marks and neuropsychiatric processes. Further work is needed to define the nature of the genetic-epigenetic interaction in the sensitivity to environmental exposure and risk to develop mental diseases in a context-dependent manner. Indeed, epigenetic changes can act: (i) in an additive manner; (ii) in synergy; or (iii) as a mediator of genetic risk. To address this issue, the use of analytical methods (e.g. causal inference testing 131 and Mendelian randomization 132 ) or methodological approaches, such as the use of longitudinal cohorts 133 would greatly help in deciphering the epigenetic contribution to disease. Finally, the use of adequate experimental models in rodents or in vitro systems, such as human inducible pluripotent cells derived from patients, 134 in combination with an epigenome-editing approach, could open new avenues to unravel the biological relevance of epigenetic changes.
Conceptual challenge: Vulnerability versus resilience
Experience-induced phenotypic outcomes can greatly vary between studies, leading to divergent results depending on the cohort designed or the experimental model used. 135 These discrepancies highlight the difficulty to conceptualize and test the impact of life adversity on the vulnerability to psychiatric disorders. The 'multiple hit' hypothesis, akin to the classical diathesis-stress model, proposes that frequent or chronic stressful events increase, in a cumulative manner, the allostatic load leading to vulnerability to future stressors later in life. 136 Even though this model has been influential in understanding the factors predisposing to mental illness, it appears limited by the predominant focus on risk factors over positive/protective ones. 78 A second concept called the 'match/mismatch' hypothesis states that early life events condition coping strategies that shape the individual's ability to face similar situations later on, showing vulnerability and/or resilience. 137, 138 Recent studies have suggested that these theories are not exclusive but rather both explain the individual likelihood to stress resilience/ vulnerability and further susceptibility to psychopathology. 139 Accordingly, early life stress does not necessarily lead to a compromised adaptive capacity in adulthood but can promote resilience in adulthood 140 through epigenetic mechanism. 141 Thus, it seems that multiple parameters jointly shape the individual's variability in stress-coping strategies and likelihood to manifest resilience or vulnerability. These effects are likely mediated by epigenetic mechanisms in combination with 'plasticity' genes. More comprehensive investigation of resilience, as the counterpart of risk to psychopathology, might ensure interesting prospects for more efficient prevention and treatment of psychiatric disorders.
CONCLUSION
Epigenetic studies show promising outcomes at multiple levels for the care of psychiatric patients (Fig. 3b) . First, they have high potential to understand phenotype heterogeneity for a given environmental insult or genetic variation and to provide additional information about the putative mechanisms underlying psychiatric disease. Moreover, epigenetic studies can provide robust biomarkers for an improved stratification of patients beyond phenotypic expression, a better understanding and prediction of treatment response, as well as prognosis. Finally, long-term outcomes include the use of targeted epigenetic treatment as a therapeutic tool for future personalized medicine. Overall, epigenetic research supports a nomothetic strategy toward a biopsychosocial approach in psychiatry, where psychosocial therapy combined with pharmacological treatment would jointly contribute to an epigenetic reprogramming favoring alleviation of symptoms and eventually disease recovery. To this end, the elucidation of the complexity of psychiatric diseases requires more effort in order to overcome the challenges associated with epigenetic research in general and in psychiatry in particular, and to unravel the intricate interplay between an individual's life experience, genetic risk, and epigenetic processes. Future research in epigenetics appears essential to further integrate encouraging scientific findings into a clinical perspective.
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